Target Name: USP45
NCBI ID: G85015
Review Report on USP45 Target / Biomarker Content of Review Report on USP45 Target / Biomarker
USP45
Other Name(s): ubiquitin thioesterase 45 | deubiquitinating enzyme 45 | Ubiquitin carboxyl-terminal hydrolase 45 | LCA19 | ubiquitin-specific-processing protease 45 | ubiquitin specific protease 45 | Ubiquitin specific protease 45 | Deubiquitinating enzyme 45 | ubiquitin specific peptidase 45 | Ubiquitin thioesterase 45 | ubiquitin thiolesterase 45 | Ubiquitin-specific-processing protease 45 | UBP45_HUMAN | USP45 variant 1 | Ubiquitin thiolesterase 45 | Ubiquitin carboxyl-terminal hydrolase 45 (isoform a) | Ubiquitin specific peptidase 45, transcript variant 1

USP45: A Potential Drug Target and Biomarker

Ubiquitin thioesterase 45 (USP45) is a protein that plays a critical role in the regulation of cellular processes. It is a 45 kDa protein that belongs to the ubiquitin family of proteins. Ubiquitin is a small protein that is involved in the degradation of other proteins. It functions by covalently attaching to the target protein and facilitating its degradation.

USP45 is a key enzyme in the ubiquitin pathway, which is a process that is involved in the degradation of damaged or unnecessary proteins. It is part of the 26S subcomplex of the ubiquitin machinery, which is responsible for the degradation of Ub8-200. Ub8-200 is a protein that is involved in the development and maintenance of the endoplasmic reticulum. When Ub8-200 is not properly degraded, it can cause various diseases, including neurodegenerative diseases.

Research has suggested that USP45 may be a potential drug target and biomarker for various diseases. For example, USP45 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have also suggested that USP45 may be involved in the development of cancer. For instance, USP45 has been shown to be involved in the regulation of cell cycle progression and has been linked to the development of various types of cancer.

In addition to its potential drug-targeting properties, USP45 has also been shown to be a potential biomarker for various diseases. For example, USP45 has been shown to be involved in the diagnosis of Alzheimer's disease. Studies have shown that USP45 levels are significantly decreased in the brains of individuals with Alzheimer's disease, and that inhibiting USP45 activity may be a potential diagnostic or therapeutic approach for this disease.

Another potential application of USP45 is its role in the regulation of cellular processes. USP45 has been shown to play a critical role in the regulation of cell signaling pathways, such as the JAK/STAT signaling pathway. This pathway is involved in the regulation of immune responses and has been implicated in various diseases, including cancer. Therefore, USP45 may be a potential target for small molecule inhibitors that can modulate this pathway and have therapeutic applications in diseases such as cancer.

In conclusion, USP45 is a protein that plays a critical role in the regulation of cellular processes and has been shown to be involved in the development and maintenance of various diseases. Its potential drug-targeting and biomarker properties make it an attractive target for further research and development. Further studies are needed to fully understand the role of USP45 in disease and to develop effective therapies that can modulate its activity.

Protein Name: Ubiquitin Specific Peptidase 45

Functions: Catalyzes the deubiquitination of SPDL1 (PubMed:30258100). Plays a role in the repair of UV-induced DNA damage via deubiquitination of ERCC1, promoting its recruitment to DNA damage sites (PubMed:25538220). May be involved in the maintenance of photoreceptor function (PubMed:30573563). May play a role in normal retinal development (By similarity). Plays a role in cell migration (PubMed:30258100)

The "USP45 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP45 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1 | VAT1L | VAV1 | VAV2 | VAV3 | VAV3-AS1 | VAX1 | VAX2 | VBP1 | VCAM1 | VCAN | VCL | VCP | VCPIP1 | VCPKMT | VCX | VCX2 | VCX3A | VCX3B | VCY | VCY1B | VDAC1 | VDAC1P2 | VDAC1P9 | VDAC2 | VDAC2P5 | VDAC3 | VDR | VEGFA | VEGFB | VEGFC | VEGFD